meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
9
mML - NA - PDL1 positive
1
mML - 1st line (L1)
mML - L1 - all population
7
mML - L1 - BRAF mutant
2
mML - L1 - BRAF wild
3
mML - 2nd line (L2)
mML - L2 - all population
11
mML - L2 - BRAF mutant
1
mesothelioma (MS)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg)
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs Ipilimumab (10 mg/kg)
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
vs Immunostimulant
vs interferon alpha
vs non active control
vs placebo
All patients
stage IIIa
stage IIIb
stage IIIc
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
deaths (OS) (extension)
MFS
MFS (extension)
RFS (extension)
RFS/DFS
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
Colitis TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Endocrine disorders TRAE (grade 3-4)
Gastrointestinal disorders TRAE (grade 3-4)
Hepatobiliary disorders TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Nervous system disorders TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Skin and subcutaneous tissue disorders TRAE (grade 3-4)
Abdominal pain AE (grade 3-4)
Colitis AE (grade 3-4)
Cough AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Fatigue AE (grade 3-4)
Headache AE (grade 3-4)
Hypophysitis AE (grade 3-4)
Hypothyroidism AE (grade 3-4)
Increase AST AE (grade 3-4)
Increased ALT AE (grade 3-4)
Nausea AE (grade 3-4)
Pruritus AE (grade 3-4)
Pyrexia AE (grade 3-4)
Rash AE (grade 3-4)
Vomiting AE (grade 3-4)
Weight decreased AE (grade 3-4)
deaths (OS)
mML - NA - all population
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
versus interferon alpha
Ipilimumab (10 mg/kg) vs. interferon alpha
1
certainty unassessable
-11%
versus placebo
Ipilimumab (10 mg/kg) vs. placebo
1
certainty unassessable
statistically conclusive
-26%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open